Mankind Pharma to invest Rs 200cr to open 2 plants by mid-2016
Advertisement
New Delhi, Nov 29 (PTI) Drug firm Mankind Pharma will invest Rs 200 crore to open two manufacturing plants in the country by the middle of 2016 as part of its expansion plans. "We plan to invest Rs 200 crore, excluding the land cost, to open two plants by middle of 2016. One of them will be in Sikkim and the other one at Behror in Rajasthan," Mankind Pharma Managing Director Sheetal Arora told PTI.
The Sikkim plant, which will entail an investment of Rs 150 crore, will be opened by March 2016, while the Behror plant would require around Rs 50 crore and will be ready by middle of next year, he added.
When asked how the company would finance the expansion, Arora said: "It will all be through internal accruals." The Behror facility will focus on Active Pharmaceutical Ingredients (APIs), while Sikkim plant will focus on products for different segments of the firm, he added.
The company will also open "a plant at Udaipur by the end of 2017 or early 2018", Arora said adding that they already have land for that. Mankind Pharma recently launched anti-diabetic drug Gliptin under the brand name Dynaglipt at Rs 8.5 per tablet for the patients and expects diabetes segment to contribute Rs 200 crore to the companys expected revenues of around Rs 4,200 crore for the fiscal.
The company has an employee base of over 12,000 and expects to add around 3,000 more people with the opening of three plants. "With the opening of three more plants we will be adding around 3,000 employees in various activities including R&D by 2018," Arora said.
The Sikkim plant, which will entail an investment of Rs 150 crore, will be opened by March 2016, while the Behror plant would require around Rs 50 crore and will be ready by middle of next year, he added.
When asked how the company would finance the expansion, Arora said: "It will all be through internal accruals." The Behror facility will focus on Active Pharmaceutical Ingredients (APIs), while Sikkim plant will focus on products for different segments of the firm, he added.
The company will also open "a plant at Udaipur by the end of 2017 or early 2018", Arora said adding that they already have land for that. Mankind Pharma recently launched anti-diabetic drug Gliptin under the brand name Dynaglipt at Rs 8.5 per tablet for the patients and expects diabetes segment to contribute Rs 200 crore to the companys expected revenues of around Rs 4,200 crore for the fiscal.
The company has an employee base of over 12,000 and expects to add around 3,000 more people with the opening of three plants. "With the opening of three more plants we will be adding around 3,000 employees in various activities including R&D by 2018," Arora said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.